On behalf of Pernix Therapeutics, Dr. Ira Turner (Neurologist/Headache specialist at Island Neurological Associates, Plainview, NY) describes how he approaches treating migraines, including best practices for different age groups and treatment during pregnancy.
TREXIMET® (sumatriptan and naproxen sodium) is a combination of sumatriptan, a serotonin (5-HT) 1b/1d receptor agonist (triptan), and naproxen sodium, a non-steroidal anti-inflammatory drug, indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.
LIMITATIONS OF USE
WARNINGS AND PRECAUTIONS
The most common adverse reactions (incidence ≥2%) were:
You are encouraged to report negative side effects of taking TREXIMET® to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
To report adverse events, a product complaint, or for additional information about TREXIMET®, call Pernix Therapeutics at 1-877-745-3667.
Please see Full Prescribing Information, including Boxed WARNINGS, before prescribing TREXIMET®.